Orchard Therapeutics PLC
Brian A. Campbell is an experienced executive in global commercial operations, currently serving as Executive Director at Orchard Therapeutics since August 2019, focusing on the global launch and commercialization of hematopoietic stem cell gene therapy. Brian's extensive career includes roles in both commercial leadership and military service, with past positions at Sanofi Genzyme, Mallinckrodt Pharmaceuticals, and Bristol-Myers Squibb, among others. Additionally, Brian dedicates time as a volunteer USNA Blue & Gold Officer and has held various leadership positions within the U.S. Navy Reserves, culminating in a retired commander status. Brian's educational background includes a Bachelor of Science in Engineering from the United States Naval Academy and an MBA from The University of Alabama.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.